Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Dore

Showing results (371-380 of 404) with videos related to

Pageof 41
Sort By:
Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.
Nature Communications|April 17, 2024
Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infectionChansavath Phetsouphanh, Brendan Jacka, Sara Ballouz, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infectionJason Grebely, Kimberly Page, Rachel Sacks-Davis, et al.
Journal of Hepatology|September 1, 2015
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trialsGregory J Dore, Brian Conway, Yan Luo, et al.
Annals of Internal Medicine|August 8, 2022
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort StudyJason Grebely, Gregory J Dore, Frederick L Altice, et al.
The International Journal on Drug Policy|May 25, 2024
Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugsTimothy R Broady, Heather Valerio, Maryam Alavi, et al.
Hepatology Communications|February 7, 2018
Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic reviewSofia R Bartlett, Jason Grebely, Auda A Eltahla, et al.
JAMA|May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosisAndrew J Muir, Fred Poordad, Jacob Lalezari, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|January 10, 2017
Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infectionChaturaka Rodrigo, Melanie R Walker, Preston Leung, et al.
Annals of Internal Medicine|August 19, 2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized TrialGregory J Dore, Frederick Altice, Alain H Litwin, et al.
Pageof 41

Showing results (371-380 of 404) with videos related to

Sort By:
Pageof 41
Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.
Nature Communications|April 17, 2024
Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infectionChansavath Phetsouphanh, Brendan Jacka, Sara Ballouz, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infectionJason Grebely, Kimberly Page, Rachel Sacks-Davis, et al.
Journal of Hepatology|September 1, 2015
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trialsGregory J Dore, Brian Conway, Yan Luo, et al.
Annals of Internal Medicine|August 8, 2022
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort StudyJason Grebely, Gregory J Dore, Frederick L Altice, et al.
The International Journal on Drug Policy|May 25, 2024
Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugsTimothy R Broady, Heather Valerio, Maryam Alavi, et al.
Hepatology Communications|February 7, 2018
Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic reviewSofia R Bartlett, Jason Grebely, Auda A Eltahla, et al.
JAMA|May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosisAndrew J Muir, Fred Poordad, Jacob Lalezari, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|January 10, 2017
Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infectionChaturaka Rodrigo, Melanie R Walker, Preston Leung, et al.
Annals of Internal Medicine|August 19, 2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized TrialGregory J Dore, Frederick Altice, Alain H Litwin, et al.
Pageof 41